Browse > Article

Effect of Pretreatment of Naringin on the Bioavailability of Diltiazem and Deacetyldiltiazem in Rabbits  

Kim Hyuong Joong (Korean Food and Drug Administration)
Choi Jun Shik (College of Pharmacy, Chosun University)
Publication Information
YAKHAK HOEJI / v.49, no.3, 2005 , pp. 230-236 More about this Journal
Abstract
The purpose of this study was to investigate the effect of naringin pretreatment on the bioavailability and phar-macokinetics of diltiazem and one of its metabolites, deacetyldiltiazem, in rabbits. Pharmacokinetic parameters of diltiazem and deacetyldiltiazem were determined after oral administration of diltiazem (15 mg/kg) pretreated with naringin (1.5, 7.5 and 15 mg/kg). Absorption rate constant ($k_a$) of diltiazem after oral administration of diltiazem pretreated with naringin was significantly (p<0.05 or p<0.0l) increased compared to the control group. Area under the plasma concentration-time curve (AUC) and peak concentration ($C_{max}$) of the diltiazem were significantly (p<0.05 or p<0.01) higher than those of the control. Absolute bioavailability ($AB\%$) of diltiazem pretreated with naringin ranged from $13.5\%$ to $18.6\%$, being enhanced compared to that of the control, $7.2\%$. Relative bioavailability ($RB\%$) of diltiazem was $1.9\~2.6$ times higher than that of the control group. There was no significant change in terminal half-life ($t_{1/2}$) and $T_{max}$ of diltiazem in the presence of naringin. AUC of deacetyldiltiazem pretreated with naringin was significantly (p<0.05) higher than (p<0.05) that of the control. But the metabolite ratios (MR) were significantly decreased (p<0.05), implying that pretreatment of naringin could be effective to inhibit the CYP 3A4-mediated metabolism of diltiazem. In this study, pretreatment of naringin significantly enhanced the oral bioavailability of diltiazem. These results suggested that the diltiazem dosage should be adjusted when it is administered with naringin or a naringin-containing dietary supplement in the clinical setting.
Keywords
diltiazem; naringin; deacetyldiltiazem; bioavailability; pharmacokinetics; CYP 3A4; pretreatment; rabbits;
Citations & Related Records
연도 인용수 순위
  • Reference
1 AHFS Drug Information, AFS 1317 (1988)
2 Scholz, H. : Pharmacological aspects of calcium channel blockers. Cardiovas. Drugs Ther. 10, 869 (1997)   DOI   ScienceOn
3 Eichelbaum, M. and Echizen, H. : Clinical pharmacology of calcium antagonists: A critical review.J. Cardiovas. Pharmacol. 6, 963 (1984)   DOI
4 Bianchetti, G., Regazzi, M., Rondanelli, R., Ascalone, V. and Morselli, P. L. : Bioavailability of diltiazem as a function of the administered dose. Biopharm. Drug Dispos. 12, 391 (1991)   DOI   ScienceOn
5 Watkins, P. B., Wrighton, S. A., Schuetz, E. G., Molowa, D. T. and Guzelian, P. S. : Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J. Clin. Invest. 80, 1029 (1987)   DOI   PUBMED
6 Lefebvre, M., Homsy, W., Caille, G. and du Souich, P. : Firstpass metabolism of diltiazem in anesthetized rabbits: Role of extrahepatic organs. Pharm. Res. 13, 124 (1996)   DOI   ScienceOn
7 Homsy, W., Caille. G. and du Souich, P. : The site of absorption in the small intestine determines diltiazem bioavailability in the rabbit. Pharm. Res. 12, 1722 (1995)   DOI   ScienceOn
8 Dixon, R. A. and Steele, C. : Flavonoids and isoflavonoids-gold mine for metabolic engineering. Trends Plant Sci. 4, 394 (1999)   DOI   ScienceOn
9 Dupuy, J., Larrieu, G., Sutra, J. F., Lespine, A. and Alvinerie, M. : Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: Quercetin. Vet. Parasitol. 112, 337 (2003)   DOI   ScienceOn
10 Zhang, H., Wong, C. W., Coville, P. G. and Wanwimolruk, S. : Effect of the grapefruit flavonoid naringin on pharmacokinetics of quinine in rats. Drug Meta. Drug Interact. 17, 351 (2000)
11 Goebel, K. J. and Kolle, E. U. : High performance liquid chromatographic dertermination of diltiazem and four of its metabolites in plasma. J. Chromatogr. 345, 355 (1985)   DOI   ScienceOn
12 Hodek, P., Trefil, P. and Stiborova, M. : Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem. Biol. Interact. 139, 1 (2002)   DOI   ScienceOn
13 Klaassen, C. D. Toxicology. 5th ed. New York: McGraw-Hill. 113 (1999)
14 Yusa, K. and Tsuruo, T. : Reversal mechanism of multidrug resistance by verapamil: Direct binding of verapamil to Pglycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res. 49, 5002 (1989)
15 Takanaga, H., Ohnishi, A., Matsuo, H. and Sawada, Y. : Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells. Biol. Pharm. Bull. 21, 1062 (1998)   DOI   ScienceOn
16 Ford, J. M. : Modulators of multidrug resistancepreclinical studies. Hematol. Oncol. Clin. N. Am. 9, 337 (1995)   PUBMED
17 Saeki, T., Ueda, K., Tanigawara, Y., Hori, R. and Komano, T. : P-glycoprotein-mediated transcellular transport of MDR-reversing agents. FEBS Lett. 324, 99 (1993)   DOI   ScienceOn
18 Fruehauf, J. P. and Manetta, A. : Use of extreme drug resistance assay to evaluate mechanisms of resistance in ovarian cancer: Taxol resistance and MDRI expression. Contrib. Gynecol. Obstet. 19, 39 (1994)
19 Yeung, P. K., Mosher, S. J., Quilliam, M. A. and Montague, T. J. : Species comparison of pharmacokinetics and metabolism of diltiazem in humans, dogs, rabbits and rats. Drug Metab. Dispos. 18, 1055 (1990)
20 Van Asperen, J., Van Tellingen, O., Sparreboom, A., Schinkel, A. H., Borst, P., Nooijen, W. J. and Beijnen, J. H. : Enhanced oral bilavailability of diltiazem in mice treated with the p-glycoprotein blocker SDZ PSC 833. Br. J. Cancer 76, 1181 (1997)   DOI   ScienceOn
21 Kim, D. H., Jung, E. A., Sohng, I. S., Han, J. A., Kim, T. H. and Han, M. J. : Intestinal bacterial metabolism of flavonoids and its relation to some biological activities. Arch. Pharm. Res. 21, 17 (1998)   DOI
22 Bardelmeijer, H. A., Beijnen, J. H., Brouwer, K. R., Rosing, H., Nooijen, W.J., Schellens,J. H. and van Tellingen, O. : Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin. Cancer Res. 6, 4416 (2000)
23 Homsy, W., Lefebvre, M., Caille, G. and du Souich, P. : Metabolism of diltiazem in hepatic and extrahepatic tissues of rabbits: In vitro studies. Pharm. Res. 12, 609 (1995)   DOI   ScienceOn
24 Chaudhary, P. M. and Robinson, I. B. : Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66, 85 (1991)   DOI   ScienceOn
25 Rocci, M. L. and Jusko, W. J. : LAGRAN program for area and moments in pharmacokinetic analysis. Computer Programs in Biomedicine. 16, 203 (1983)   DOI   ScienceOn
26 Gottesman, M. M. and Pastan, I. : Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385 (1993)   DOI   ScienceOn
27 Ito, K., Kusuhara, H. and Sugiyama, Y. : Effects of intestinal CYP 3A4 and P-glycoprotein on oral drug absorption-theoretical approach. Pharm. Res. 16, 225 (1999)   DOI   ScienceOn
28 Sterzel, P. B. : Renal actions of calcium antagonists.J. Cardiovas. Pharmacol. 10, 17 (1987)   DOI
29 Biedler, J. L. and Riehm, H. : Cellular resistance to actinomycin D in Chinese hamster cells in vitro: crossresistance, radioautographic, and cytogenetic studies. Cancer Res. 30, 1174 (1970)
30 Epstein, M. and Loutzenhister, R. D. : Effects of calcium antagonists on renal hemodynamics. Am. J. Kidney Dis. 16, 10 (1990)
31 Eagling, V. A., Profit, L. and Back, D. J. : Inhibition of the CYF 3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br. J. Clin. Pharmacol. 48, 543 (1999)   DOI   ScienceOn
32 Ho, P. C., Saville, D. J. and Wanwimolruk, S. : Inhibition of human CYF 3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J. Pharm. Pharm. Sci. 4, 217 (2001)
33 Kolars, J. C., Schmiedlin-Ren, P., Dobbins, W. O., 3rd, Schuetz, J., Wrighton, S. A. and Watkins, P. B. : Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology 102, 1186 (1992)   DOI
34 The Merck Index, 12th Edition, Merck and Company., Rahway, USA. 6512 (1996)
35 Doostdar, H., Burke, M. D. and Mayer, R. T. : Bioflavonoids: Selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology 144, 31 (2000)   DOI   ScienceOn
36 Ruilope, L. M. and Alcaar,J. M. : Renal effects of calcium entry blockers. Cardiovas. Drugs Ther. 4, 979 (1990)   DOI
37 Hermann, P. H., Rodger, S. D., Remones, G., Thenot, J. P., London, D. R. and Morselli, P. L. : Pharmacokinetics of diltiazem after intravenous and oral administration. Eur. J. Clin. Pharmacol. 24, 349 (1983)   DOI   ScienceOn
38 Nijveldt, R. J., van Nood, E., van Hoom, D. E. C., Boelens, P. G., van Norren, K. and van Leeuwen, PAM. : Flavonoids: A review of probable mechanisms of action and potential applications. Am. J. Clin. Nutr. 74, 418 (2001)